8 results about "Decorin" patented technology

A pharmaceutical composition containing a stem cell secretion, and a pharmaceutically acceptable excipient thereof. The protein in the stem cell secretion comprises one, two or three proteins selected from a group consisting of a pigment epithelium-derived factor (PEDF), a tissue inhibitor of metalloproteinase 1 (TIMP-1), a secreted protein acidic and rich in cysteine (SPARC), an α2-HS glycoprotein (AHSG), a periostin (POSTN), a decorin (DCN), the retinoic acid receptor responder 2 (RARRES2), the glia-derived nexin (GDN), the Sparc / osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1), and the follistatin-like 1 (FSTL1). The pharmaceutical composition is used for treating degenerative ocular diseases including retinal degeneration, retinitis pigmentosa, glaucoma, macular degeneration, etc.

The present invention relates to an immune cell expressing a chimeric antigen receptor (CAR) and a heterologous decorin polypeptide and the medical use thereof in treaing cancer. In particular, the specification teaches a CD19 CAR- expressing T cell that secretes decorin.

Decorin or a composition containing decorin for use in the treatment of type 1 diabetes, type 2 diabetes or gestational diabetes is described herein. Decorin or a composition containing decorin is also described for use in the context of transplanting pancreatic islet cells.

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.

The present disclosure pertains to a cell that expresses at least one binding protein, such as decorin binding protein A (DbpA), decorin binding protein B (DbpB), or combinations thereof. The cell may include immune cells, such as chimeric antigen receptor T-cells. The present disclosure also pertains to methods of treating or preventing a disease in a subject by administering a cell of the present disclosure to the subject. The present disclosure also pertains to methods of forming the cells of the present disclosure by expressing at least one binding protein in the cell.

Decorin or a composition containing decorin for use in the treatment of type 1 diabetes, type 2 diabetes or gestational diabetes is described herein. Decorin or a composition containing decorin is also described for use in the context of transplanting pancreatic islet cells.

The present invention discloses the use of decorin or its encoding gene as a target in the preparation of a psoriasis treatment drug. Through a series of experiments, the present invention demonstrates that DCN can effectively protect against imiquimod-induced psoriatic skin inflammation in mice, improve skin scaling, erythema, thickening, and abnormal epidermal differentiation, enhance the skin's barrier function, reduce the infiltration of inflammatory cells, and exert a certain anti-inflammatory effect. The experimental studies of the present invention have confirmed that DCN has significant efficacy in psoriasis models, is safe, highly effective, and has no side effects, and has a simple production process, showing the potential for medical transformation. This will also help expand the potential application value of DCN in various other inflammatory skin diseases.

The present invention relates to multifunctional protein molecules comprising decorin and their uses. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody, and methods for their production and uses.